ENTWRAP
DEAD

Serial Number

77288446

Owner

Bioprogress Technology Limited

Attorney

Farah P. Bhatti, Esq.

Filing Date

Sep 25, 2007

Add to watchlist:

No watchlists yet
View on USPTO

ENTWRAP Trademark

Serial Number: 77288446

ENTWRAP is a trademark filed by Bioprogress Technology Limited on September 25, 2007. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Bioprogress Technology Limited (16 trademarks)

15-17 Cambridge Science Park,
Milton Road, Cambridge CB40FQ , GB

Entity Type: 99

Trademark Details

Filing Date

September 25, 2007

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for use in the treatment of ailments, namely, bad breath, headaches, body aches, cold and flu symptoms, pain relief, muscular disorders, orthopedic disorders, cancer, cardiovascular disorders, digestive disorders, diabetes, renal disorders, inflammation, auto-immune disorders, gastro-intestinal disorders, hormonal disorders, parasites and skin disorders; sanitary preparations for medical purposes; dietetic foods adapted for medical purposes; food for babies; material for stopping teeth, dental wax; preparations for destroying vermin; fungicides; herbicides; medicated films or strips for the treatment of diseases and disorders in humans and animals namely, oral, suppository or topical use, containing an effective dose of one or more drugs/active ingredients, namely, antiinfectives, antibiotics and antivirals; analgesics; anorexics; antihelminthics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihistamines; anti-inflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations, namely, potassium and calcium blockers, beta-blockers, alpha-blockers and antiarrhythmics; antihypertensives; diuretics and antidiuretics; vasodilators; central nervous system stimulants; vasoconstrictors; cough and cold preparations; decongestants; hormones, namely, estradiol; steroids, corticosieroids; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; sedatives; tranquilizers; and nicotine; dietetic, mineral or vitamin supplements which consist of pharmaceutical preparations for the treatment of diseases and disorders in humans and animals; medicated breath freshening preparations namely, dissolvable breath strips; fungicides, pesticides or preparations for destroying vermin; dressings for wounds, burns, surgery; oral pharmaceutical preparations in tablet, capsule, film or strip form for the treatment of bad breath, headaches, body aches, cold and flu symptoms, pain relief, muscular disorders, orthopedic disorders, cancer, cardiovascular disorders, digestive disorders, diabetes, renal disorders, inflammation, auto-immune disorders, gastro-intestinal disorders, hormonal disorders, parasites and skin disorders; pharmaceutical preparations, namely, drug delivery systems comprising polymer-based oral tablets, capsule, film or strip form for the continuous release of a wide variety of therapeutic agents; pharmaceutical products, namely, medication for the treatment of bad breath, headaches, body aches, cold and flu symptoms, pain relief, muscular disorders, orthopedic disorders, cancer, cardiovascular disorders, digestive disorders, diabetes, renal disorders, inflammation, auto-immune disorders, gastro-intestinal disorders, hormonal disorders, parasites and skin disorders; medicated lozenges; unit dose capsules sold empty for pharmaceutical use; pharmaceutical capsules filled with liquids or powders for the treatment of animals or humans, namely, oral, suppository or topical use, containing an effective dose of one or more drugs/active ingredients, namely, antiinfectives, antibiotics and antivirals; analgesics; anorexics; antihelminthics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihistamines; anti-inflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations, namely, potassium and calcium blockers, beta-blockers, alpha-blockers and antiarrhythmics; antihypertensives; diuretics and antidiuretics; vasodilators; central nervous system stimulants; vasoconstrictors; cough and cold preparations; decongestants; hormones, namely, estradiol; steroids, corticosieroids; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; sedatives; tranquilizers; and nicotine

Filing History

ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT
Apr 27, 2009 MAB1
ABANDONMENT - EXPRESS MAILED
Apr 27, 2009 ABN1
TEAS EXPRESS ABANDONMENT RECEIVED
Apr 24, 2009 EXAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 21, 2009 GNRN
NON-FINAL ACTION E-MAILED
Jan 21, 2009 GNRT
NON-FINAL ACTION WRITTEN
Jan 21, 2009 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 31, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 30, 2008 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 30, 2008 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 14, 2008 GNRN
NON-FINAL ACTION E-MAILED
Jul 14, 2008 GNRT
NON-FINAL ACTION WRITTEN
Jul 14, 2008 CNRT
AMENDMENT FROM APPLICANT ENTERED
Jun 11, 2008 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 11, 2008 CRFA
ASSIGNED TO LIE
Jun 11, 2008 ALIE
PAPER RECEIVED
Jun 9, 2008 MAIL
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 12, 2007 GNRN
NON-FINAL ACTION E-MAILED
Dec 12, 2007 GNRT
NON-FINAL ACTION WRITTEN
Dec 12, 2007 CNRT
ASSIGNED TO EXAMINER
Dec 7, 2007 DOCK
NEW APPLICATION ENTERED
Sep 28, 2007 NWAP